The Definitive Cross-Class Reference for Research Peptides

Start here

This site is a reference desk, not a shop. It exists to answer one question honestly for five widely searched research peptides: what does the published science actually say, and how far does it really reach? Research peptides are short chains of amino acids being studied in laboratories, animal models, and in some cases human trials — some, like semaglutide, have become approved medicines; others, like BPC-157 and MOTS-c, remain investigational compounds sold only for laboratory research.

Each compound gets its own page covering what it is, how it is thought to work, what the trials and animal studies found, and what people report using it for in research communities — clearly labeled as anecdotal, not clinical evidence, and never attached to a dose. A comparison page lines up all five side by side, and every factual claim on this site traces to a numbered source on the references page.

Why these five, together

Definitive Peptides was built as a definitive cross-class reference to the most-cited research peptides — five compounds that, taken individually, sit in five different corners of peptide science, and that, read together, sketch the actual state of the field. BPC-157 leads this reference because it is the compound with the widest gap between online buzz and published human evidence: a preclinical repair story built almost entirely on rodent work, with a 2025 narrative review counting only three small human pilot studies to date ^[2]. Semaglutide sits at the opposite end — a GLP-1 receptor agonist with a decade of large, sponsor-run randomized trials behind it, including the SELECT cardiovascular-outcomes study of more than 17,000 adults ^[10]. Thymosin Alpha-1 is a thymic immune peptide approved abroad for decades, whose largest and most rigorous trial — a 1,106-patient phase-3 sepsis study — found no mortality benefit in 2025 ^[13]. CJC-1295 is a growth-hormone-releasing hormone analog studied in a handful of small pharmacology trials, never approved, and flagged for immunogenicity concerns by FDA compounding reviewers ^[18]. MOTS-c is the newest entrant, a mitochondrial-derived peptide whose mechanism (AMPK activation via the folate cycle) is well characterized in cells and mice but has essentially no human interventional data behind it ^[25].

No two of these compounds share a regulatory status, an evidence tier, or a mechanism class — which is the point. Reading them side by side on the comparison page shows what "well-studied" actually looks like for a peptide, and how rarely research-community enthusiasm and published evidence move together.

What are research peptides

A peptide is simply a short chain of amino acids — smaller than a full protein, but built from the same twenty building blocks. Some peptides on this site, like semaglutide, are synthetic analogs of hormones the body already makes, chemically modified to resist breakdown so they can be dosed less often. Others, like BPC-157 and MOTS-c, are peptides identified in the body (a stomach-protective protein fragment, a peptide encoded inside mitochondrial DNA) that are now studied as standalone research compounds.

"Research peptide" is also a regulatory category: material sold by laboratory suppliers labeled not for human consumption, intended for use in cell and animal studies rather than in people. Three of the five compounds here — semaglutide (as an approved medicine) and, to a lesser degree, thymosin alpha-1 (approved in dozens of countries as thymalfasin) — have moved into approved clinical use; BPC-157, CJC-1295 and MOTS-c have not. This site marks that distinction clearly on every page, because it changes what can honestly be said about safety, dosing evidence, and legal status.

How this reference is organized

Each compound page follows the same arc: a plain-English short version, what the compound is, how it is thought to work, what the cited research shows, what research communities report using it for (labeled anecdotal), and where it fits in the broader research-peptide landscape. The comparison page puts mechanism class, evidence maturity, and regulatory status side by side in one table. The FAQ answers the specific questions people search most often about these five compounds, each answer grounded in a cited source. Nothing on this site is sold, and no page recommends a dose to any individual — that is a conversation for a licensed clinician, not a reference desk.